Radiopharmaceutical therapy offers promise for people with tough-to-treat meningioma brain tumors

A radiopharmaceutical therapy that has successfully extended progression-free survival for patients with neuroendocrine tumors shows early promise for delivering similar benefits to patients with difficult-to-treat meningioma.

Meningiomas are tumors that grow in connective tissue surrounding the brain and spinal cord.

Nearly 80% of patients in the study were progression free after six months .

177Lu-Dotatate is a safe and rational therapeutic choice with broad eligibility for patients with aggressively growing meningiomas.

Meningiomas are tumors that grow in connective tissue surrounding the brain and spinal cord.

Nearly 80% of patients in the study were progression-free after six months .

Findings of the nonrandomized phase II study will be presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

The researchers conducted a single-arm, phase II clinical trial at a large academic center.

Patients with refractory meningioma had grown at a rate of 15% or more over a six-month period.

After one year , overall survival was 88.9% .